Loading…
HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo
The aim of the present study was to compare the decline of HBV DNA during peginterferon (PEG‐IFN) therapy with spontaneous HBV DNA decline in placebo‐treated patients with hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B. A total of 136 patients who participated in a randomized trial were...
Saved in:
| Published in: | Journal of medical virology 2011-11, Vol.83 (11), p.1917-1923 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4538-6f01f0b2fabd5edbf0cf973f87667a52812f5e2b6ecc1fb2b2a45975c0bc77343 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4538-6f01f0b2fabd5edbf0cf973f87667a52812f5e2b6ecc1fb2b2a45975c0bc77343 |
| container_end_page | 1923 |
| container_issue | 11 |
| container_start_page | 1917 |
| container_title | Journal of medical virology |
| container_volume | 83 |
| creator | Hansen, Bettina E. Rijckborst, Vincent ter Borg, Martijn J. Janssen, Harry L.A. |
| description | The aim of the present study was to compare the decline of HBV DNA during peginterferon (PEG‐IFN) therapy with spontaneous HBV DNA decline in placebo‐treated patients with hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B. A total of 136 patients who participated in a randomized trial were treated with PEG‐IFN alfa‐2b for 52 weeks. These patients were compared with 167 patients who received a placebo for 48 weeks using linear mixed regression analysis. Response was defined as loss of HBeAg at the end of treatment (EOT). Overall, decline of HBV DNA at the EOT was significantly greater in the PEG‐IFN group than in the placebo group (mean decline 2.3 log vs. 1.0 log, P |
| doi_str_mv | 10.1002/jmv.22208 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_890035508</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3373013481</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4538-6f01f0b2fabd5edbf0cf973f87667a52812f5e2b6ecc1fb2b2a45975c0bc77343</originalsourceid><addsrcrecordid>eNp90UFv0zAUB3ALgVgZHPgCyBJCwCHbsxM7ybEd0ILacgDK0XLc59UlTYKdbOzb467dkJDgZMv6vfeX9SfkOYMzBsDPt7urM845FA_IiEEpkxJy9pCMgGUykZKJE_IkhC0AFCXnj8kJZyUThZQjsplNVvTdckzD0HUeQ3BtQ11DZxMcXyZdG1zvrpCajW8bZ-gGO93Hp0AndH_Dpg-096h7XNNr129oh5eu6dFbjBO09bSrtcGqfUoeWV0HfHY8T8m3D--_XsyS-efpx4vxPDGZSItEWmAWKm51tRa4riwYW-apLXIpcy14wbgVyCuJxjBb8YrrTJS5MFCZPE-z9JS8PuztfPtzwNCrnQsG61o32A5BFSVAKgQUUb75r2RCAuMpu6Uv_6LbdvBN_EdUWVwmCrGPfntQxrcheLSq826n_Y1ioPZFqViUui0q2hfHjUO1w_W9vGsmgldHoIPRtfW6MS78cVnMTYFHd35w167Gm38nqk-L1V10cphwocdf9xPa_1AyT3Ohvi-nii2-TJfzxUpB-hu2cbhE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1545085854</pqid></control><display><type>article</type><title>HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo</title><source>Wiley</source><creator>Hansen, Bettina E. ; Rijckborst, Vincent ; ter Borg, Martijn J. ; Janssen, Harry L.A.</creator><creatorcontrib>Hansen, Bettina E. ; Rijckborst, Vincent ; ter Borg, Martijn J. ; Janssen, Harry L.A.</creatorcontrib><description>The aim of the present study was to compare the decline of HBV DNA during peginterferon (PEG‐IFN) therapy with spontaneous HBV DNA decline in placebo‐treated patients with hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B. A total of 136 patients who participated in a randomized trial were treated with PEG‐IFN alfa‐2b for 52 weeks. These patients were compared with 167 patients who received a placebo for 48 weeks using linear mixed regression analysis. Response was defined as loss of HBeAg at the end of treatment (EOT). Overall, decline of HBV DNA at the EOT was significantly greater in the PEG‐IFN group than in the placebo group (mean decline 2.3 log vs. 1.0 log, P < 0.001) and varied according to HBV genotype. Viral suppression was greater in the PEG‐IFN group from week 4 throughout the entire treatment period (P < 0.001). The response rate was 32% for the PEG‐IFN group and 11% for the placebo group (P < 0.001). Among responders, HBV DNA decline was greater for patients treated with PEG‐IFN than with a placebo: the mean difference in HBV DNA decline was 0.7 log (P = 0.001) at 4 weeks and 2 log (P < 0.001) at the EOT. ALT flares (>5 times the upper limit) were associated with a greater HBV DNA decline during PEG‐IFN. In conclusion, PEG‐IFN therapy resulted in a greater HBV DNA decline in positive HBeAg patients than a placebo. The decline of HBV DNA was greater in patients with HBeAg loss or who exhibited an ALT flare during PEG‐IFN than in patients with spontaneous HBeAg loss or flares during placebo therapy. J. Med. Virol. 83:1917–1923, 2011. © 2011 Wiley‐Liss, Inc.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.22208</identifier><identifier>PMID: 21915866</identifier><identifier>CODEN: JMVIDB</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Alanine Transaminase - blood ; ALT flare ; Antiviral Agents - administration & dosage ; Biological and medical sciences ; CHB ; DNA, Viral - blood ; Female ; Fundamental and applied biological sciences. Psychology ; genotype ; HBV DNA ; Hepatitis B e Antigens - blood ; Hepatitis B virus ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - pathology ; Hepatitis B, Chronic - virology ; Human viral diseases ; Humans ; Infectious diseases ; Interferon-alpha - administration & dosage ; Liver Function Tests ; Male ; Medical sciences ; Microbiology ; Middle Aged ; Miscellaneous ; peginterferon ; Placebos - administration & dosage ; Polyethylene Glycols - administration & dosage ; Recombinant Proteins - administration & dosage ; Treatment Outcome ; Viral diseases ; Viral Load ; Viremia - diagnosis ; Virology</subject><ispartof>Journal of medical virology, 2011-11, Vol.83 (11), p.1917-1923</ispartof><rights>Copyright © 2011 Wiley‐Liss, Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4538-6f01f0b2fabd5edbf0cf973f87667a52812f5e2b6ecc1fb2b2a45975c0bc77343</citedby><cites>FETCH-LOGICAL-c4538-6f01f0b2fabd5edbf0cf973f87667a52812f5e2b6ecc1fb2b2a45975c0bc77343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24545302$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21915866$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hansen, Bettina E.</creatorcontrib><creatorcontrib>Rijckborst, Vincent</creatorcontrib><creatorcontrib>ter Borg, Martijn J.</creatorcontrib><creatorcontrib>Janssen, Harry L.A.</creatorcontrib><title>HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo</title><title>Journal of medical virology</title><addtitle>J. Med. Virol</addtitle><description>The aim of the present study was to compare the decline of HBV DNA during peginterferon (PEG‐IFN) therapy with spontaneous HBV DNA decline in placebo‐treated patients with hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B. A total of 136 patients who participated in a randomized trial were treated with PEG‐IFN alfa‐2b for 52 weeks. These patients were compared with 167 patients who received a placebo for 48 weeks using linear mixed regression analysis. Response was defined as loss of HBeAg at the end of treatment (EOT). Overall, decline of HBV DNA at the EOT was significantly greater in the PEG‐IFN group than in the placebo group (mean decline 2.3 log vs. 1.0 log, P < 0.001) and varied according to HBV genotype. Viral suppression was greater in the PEG‐IFN group from week 4 throughout the entire treatment period (P < 0.001). The response rate was 32% for the PEG‐IFN group and 11% for the placebo group (P < 0.001). Among responders, HBV DNA decline was greater for patients treated with PEG‐IFN than with a placebo: the mean difference in HBV DNA decline was 0.7 log (P = 0.001) at 4 weeks and 2 log (P < 0.001) at the EOT. ALT flares (>5 times the upper limit) were associated with a greater HBV DNA decline during PEG‐IFN. In conclusion, PEG‐IFN therapy resulted in a greater HBV DNA decline in positive HBeAg patients than a placebo. The decline of HBV DNA was greater in patients with HBeAg loss or who exhibited an ALT flare during PEG‐IFN than in patients with spontaneous HBeAg loss or flares during placebo therapy. J. Med. Virol. 83:1917–1923, 2011. © 2011 Wiley‐Liss, Inc.</description><subject>Adult</subject><subject>Alanine Transaminase - blood</subject><subject>ALT flare</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>CHB</subject><subject>DNA, Viral - blood</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>genotype</subject><subject>HBV DNA</subject><subject>Hepatitis B e Antigens - blood</subject><subject>Hepatitis B virus</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - pathology</subject><subject>Hepatitis B, Chronic - virology</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Liver Function Tests</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>peginterferon</subject><subject>Placebos - administration & dosage</subject><subject>Polyethylene Glycols - administration & dosage</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral Load</subject><subject>Viremia - diagnosis</subject><subject>Virology</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp90UFv0zAUB3ALgVgZHPgCyBJCwCHbsxM7ybEd0ILacgDK0XLc59UlTYKdbOzb467dkJDgZMv6vfeX9SfkOYMzBsDPt7urM845FA_IiEEpkxJy9pCMgGUykZKJE_IkhC0AFCXnj8kJZyUThZQjsplNVvTdckzD0HUeQ3BtQ11DZxMcXyZdG1zvrpCajW8bZ-gGO93Hp0AndH_Dpg-096h7XNNr129oh5eu6dFbjBO09bSrtcGqfUoeWV0HfHY8T8m3D--_XsyS-efpx4vxPDGZSItEWmAWKm51tRa4riwYW-apLXIpcy14wbgVyCuJxjBb8YrrTJS5MFCZPE-z9JS8PuztfPtzwNCrnQsG61o32A5BFSVAKgQUUb75r2RCAuMpu6Uv_6LbdvBN_EdUWVwmCrGPfntQxrcheLSq826n_Y1ioPZFqViUui0q2hfHjUO1w_W9vGsmgldHoIPRtfW6MS78cVnMTYFHd35w167Gm38nqk-L1V10cphwocdf9xPa_1AyT3Ohvi-nii2-TJfzxUpB-hu2cbhE</recordid><startdate>201111</startdate><enddate>201111</enddate><creator>Hansen, Bettina E.</creator><creator>Rijckborst, Vincent</creator><creator>ter Borg, Martijn J.</creator><creator>Janssen, Harry L.A.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7TM</scope><scope>7X8</scope></search><sort><creationdate>201111</creationdate><title>HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo</title><author>Hansen, Bettina E. ; Rijckborst, Vincent ; ter Borg, Martijn J. ; Janssen, Harry L.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4538-6f01f0b2fabd5edbf0cf973f87667a52812f5e2b6ecc1fb2b2a45975c0bc77343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Alanine Transaminase - blood</topic><topic>ALT flare</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>CHB</topic><topic>DNA, Viral - blood</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>genotype</topic><topic>HBV DNA</topic><topic>Hepatitis B e Antigens - blood</topic><topic>Hepatitis B virus</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - pathology</topic><topic>Hepatitis B, Chronic - virology</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Liver Function Tests</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>peginterferon</topic><topic>Placebos - administration & dosage</topic><topic>Polyethylene Glycols - administration & dosage</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral Load</topic><topic>Viremia - diagnosis</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hansen, Bettina E.</creatorcontrib><creatorcontrib>Rijckborst, Vincent</creatorcontrib><creatorcontrib>ter Borg, Martijn J.</creatorcontrib><creatorcontrib>Janssen, Harry L.A.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hansen, Bettina E.</au><au>Rijckborst, Vincent</au><au>ter Borg, Martijn J.</au><au>Janssen, Harry L.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J. Med. Virol</addtitle><date>2011-11</date><risdate>2011</risdate><volume>83</volume><issue>11</issue><spage>1917</spage><epage>1923</epage><pages>1917-1923</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><coden>JMVIDB</coden><abstract>The aim of the present study was to compare the decline of HBV DNA during peginterferon (PEG‐IFN) therapy with spontaneous HBV DNA decline in placebo‐treated patients with hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B. A total of 136 patients who participated in a randomized trial were treated with PEG‐IFN alfa‐2b for 52 weeks. These patients were compared with 167 patients who received a placebo for 48 weeks using linear mixed regression analysis. Response was defined as loss of HBeAg at the end of treatment (EOT). Overall, decline of HBV DNA at the EOT was significantly greater in the PEG‐IFN group than in the placebo group (mean decline 2.3 log vs. 1.0 log, P < 0.001) and varied according to HBV genotype. Viral suppression was greater in the PEG‐IFN group from week 4 throughout the entire treatment period (P < 0.001). The response rate was 32% for the PEG‐IFN group and 11% for the placebo group (P < 0.001). Among responders, HBV DNA decline was greater for patients treated with PEG‐IFN than with a placebo: the mean difference in HBV DNA decline was 0.7 log (P = 0.001) at 4 weeks and 2 log (P < 0.001) at the EOT. ALT flares (>5 times the upper limit) were associated with a greater HBV DNA decline during PEG‐IFN. In conclusion, PEG‐IFN therapy resulted in a greater HBV DNA decline in positive HBeAg patients than a placebo. The decline of HBV DNA was greater in patients with HBeAg loss or who exhibited an ALT flare during PEG‐IFN than in patients with spontaneous HBeAg loss or flares during placebo therapy. J. Med. Virol. 83:1917–1923, 2011. © 2011 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>21915866</pmid><doi>10.1002/jmv.22208</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-6615 |
| ispartof | Journal of medical virology, 2011-11, Vol.83 (11), p.1917-1923 |
| issn | 0146-6615 1096-9071 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_890035508 |
| source | Wiley |
| subjects | Adult Alanine Transaminase - blood ALT flare Antiviral Agents - administration & dosage Biological and medical sciences CHB DNA, Viral - blood Female Fundamental and applied biological sciences. Psychology genotype HBV DNA Hepatitis B e Antigens - blood Hepatitis B virus Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - pathology Hepatitis B, Chronic - virology Human viral diseases Humans Infectious diseases Interferon-alpha - administration & dosage Liver Function Tests Male Medical sciences Microbiology Middle Aged Miscellaneous peginterferon Placebos - administration & dosage Polyethylene Glycols - administration & dosage Recombinant Proteins - administration & dosage Treatment Outcome Viral diseases Viral Load Viremia - diagnosis Virology |
| title | HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T23%3A56%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HBV%20DNA%20suppression%20in%20HBeAg-positive%20chronic%20hepatitis%20B%20patients%20treated%20with%20peginterferon%20or%20placebo&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Hansen,%20Bettina%20E.&rft.date=2011-11&rft.volume=83&rft.issue=11&rft.spage=1917&rft.epage=1923&rft.pages=1917-1923&rft.issn=0146-6615&rft.eissn=1096-9071&rft.coden=JMVIDB&rft_id=info:doi/10.1002/jmv.22208&rft_dat=%3Cproquest_cross%3E3373013481%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4538-6f01f0b2fabd5edbf0cf973f87667a52812f5e2b6ecc1fb2b2a45975c0bc77343%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1545085854&rft_id=info:pmid/21915866&rfr_iscdi=true |